Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-111 in Recurrent Glioblastoma Multiforme
NCT01260506Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Dec 2010
- Primary completion
- Jul 2015
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of ofranergene obadenovec in glioblastoma multiforme (GBM), sponsored by VBL Therapeutics. Started Dec 2010; status: completed.
02
Drugs
ofranergene obadenovec
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01260506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01260506.